Skip to main content
MED
NYSE Manufacturing

Director Kiai Parsa Adds $529K More in Medifast Stock, Extending Accumulation Streak

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Industrial
Sentiment info
Positive
Importance info
7
Price
$11.95
Mkt Cap
$133.609M
52W Low
$9.22
52W High
$14.67
52W Position info
30% above low
Off High info
19% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

MED sits 30% above its 52-week low of $9.22 on light trading volume (0.1× avg).

Summary

Director Kiai Parsa purchased 43,150 shares of Medifast for $529,157 on August 26, following a larger purchase disclosed days earlier. The buying extends a pattern of insider accumulation amid operational headwinds.


Key Events · Ownership and Investor Activity · MED

  • Director Buys $529K More Stock

    Kiai Parsa acquired 43,150 shares at an average price of $12.26 on August 26, 2026, for a total of $529,157.08.

  • Extends Accumulation Streak

    This follows a $842,699 purchase disclosed on August 21, bringing Parsa's total open-market buying over the past week to approximately $1.37 million.

  • Steamboat Capital Connection

    The shares are held indirectly through Steamboat Capital Partners funds, which recently disclosed a 7.1% stake in Medifast.

  • Operational Headwinds Persist

    The purchases come after Q2 2026 revenue fell 27.6% to $76.4M and the company swung to a $3.1M net loss, with active coaches down 48.7% year-over-year.


Analysis · MED · Manufacturing

Director Kiai Parsa bought another $529,157 worth of Medifast stock on August 26, just days after a $842,699 purchase disclosed on August 21. The combined buying over the past week totals roughly $1.37 million, a meaningful show of conviction from a director with ties to Steamboat Capital Partners, which recently disclosed a 7.1% stake. The purchases come against a backdrop of steep revenue declines and a net loss in Q2 2026, making the insider accumulation notable.

How filings like this one have moved

In the 30 days to Sep 14, 2026, 29.9% of the 1591 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.24%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, MED was trading at $11.95 on NYSE in the Manufacturing sector, with a market capitalization of approximately $133.6M. The 52-week trading range was $9.22 to $14.67. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

MED - Latest Insights

MED
Aug 21, 2026, 4:01 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $11.95
Real-time Price: $12.08 info
Change: +$0.130 (+1%) info
Market Cap: $135.063M info
MED
Aug 21, 2026, 12:35 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $11.56
Real-time Price: $12.08 info
Change: +$0.520 (+4%) info
Market Cap: $135.063M info
MED
Aug 03, 2026, 4:50 PM EDT
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $12.80
Real-time Price: $12.08 info
Change: -$0.720 (-6%) info
Market Cap: $135.063M info
MED
Aug 03, 2026, 4:12 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $10.78
Real-time Price: $12.08 info
Change: +$1.30 (+12%) info
Market Cap: $135.063M info
MED
Jun 01, 2026, 9:03 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $13.19
Real-time Price: $12.08 info
Change: -$1.11 (-8%) info
Market Cap: $135.063M info